María Natalia Gandur Quiroga: Fantastic review! A pleasure to read: Understanding the Cancer-Immunity Cycle.

Quoting María Natalia Gandur Quiroga on X/Twitter:

“Fantastic review! A pleasure to read: Understanding the Cancer-Immunity Cycle by Dan Chen, Tom Powles, Ira Mellman and Shannon Turley.

Framework for Anti-Cancer Immune Responses:

• Describes events initiating anti-cancer immune responses.  
• Emphasizes iterative nature: T cell killing, antigen presentation and T cell stimulation.
• Any cycle step can limit immune system, enabling tumor growth.

Recent Advances:    

• Updated cycle based on past decade progress.    
• Checkpoint inhibition and dendritic cells’ role evolved.    
• Tumor microenvironment’s impact considered, discussing tumor immunological phenotype (”immunotype”).

 Clinical Application:    

• Immune checkpoint inhibition (ICI) success, especially PD-L1/PD-1 therapy.  
• ICI in perioperative setting, reducing relapse rates, transforming outcomes in specific cancers.
• Challenges: optimal ICI therapy duration, immune memory, and rechallenging with PD-(L)1 therapy.

 Combination Therapies:    

• Established PD-1 and CLTA4 inhibition.    
• Second-generation therapies, like LAG-3, and interest in TIGIT.    
• Personalized cancer vaccines, CAR-T cell therapy, and T cell engagers explored for effectiveness.  
• Targeting tumor microenvironment with non-immune therapy explored.  

 Biomarkers and Challenges:    

• Complex mechanisms of sensitivity and resistance.    
• Need for unified biomarkers beyond PD-L1 or TMB.    
• Challenges: suboptimal trial conditions, patient heterogeneity, and identifying appropriate steps for effective anti-cancer response.

 Future Outlook:    

• Focus on tumor immunotypes, shared immune escape mechanisms, and early disease settings.
• Continued efforts needed for revolutionizing cancer-immunity cycle.

Must read it here.”

Source: María Natalia Gandur Quiroga/Twitter

María Natalia Gandur Quiroga is a Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Instituto de Oncología Ángel H. Roffo in Buenos Aires, Argentina. She is a Professor of Medicine at the University of Buenos Aires at the Oncologists Post Graduates Studies. Her research focuses on clinical trials with aims to improve the treatment of patients with urologic tumors.  She is an active member of the European Association for Cancer Research, Argentinian Medical Association and American Society of Clinical Oncology.